Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10516 in Advanced Clear Cell Renal Cell Carcinoma
NCT06049030Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of HS-10516 in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose / Maximum Acceptable Dose at 2 months and Objective Response Rate at 1 year. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
HS-10516
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06049030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049030.